The present invention generally relates to novel pharmaceutical formulations containing 2-[3,5-Bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-3-pyridinyl}-N,2-dimethylpropanamide, methods of preparation thereof and their use in medical therapy.

Compositions and methods for treating cancer are provided. In particular, the compositions comprise an anti-neoplastic agent and either an interferon type I agonist or an interferon type II agonist, or a combination of an interferon type I agonist and an interferon type II agonist.

A prophylactic or therapeutic pharmaceutical agent for HIV infectious diseases, said pharmaceutical agent being characterized by comprising a combination of: (A) a compound represented by formula (I) (wherein ring A represents a non-aromatic heterocyclic ring; ring B represents a benzene ring or a pyridine ring; Q represents —NHC(O)— or the like: each R.sup.1 independently represents a halogen atom or the like: each of R.sup.2a and R.sup.2b independently represents a hydrogen atom or the like: R.sup.3 represents an alkyl group or a haloalky 1 group: R.sup.4 represents a hydrogen atom or an alkyl group: and n represents an integer from 1 to 3) or a pharmaceutically acceptable salt thereof, and (B) a compound having an anti-HIV effect or a pharmaceutically acceptable salt thereof.

##STR00001##

A prophylactic or therapeutic pharmaceutical agent for HIV infectious diseases, said pharmaceutical agent being characterized by comprising a combination of: (A) a compound represented by formula (I) (wherein ring A represents a non-aromatic heterocyclic ring; ring B represents a benzene ring or a pyridine ring; Q represents —NHC(O)— or the like: each R.sup.1 independently represents a halogen atom or the like: each of R.sup.2a and R.sup.2b independently represents a hydrogen atom or the like: R.sup.3 represents an alkyl group or a haloalky 1 group: R.sup.4 represents a hydrogen atom or an alkyl group: and n represents an integer from 1 to 3) or a pharmaceutically acceptable salt thereof, and (B) a compound having an anti-HIV effect or a pharmaceutically acceptable salt thereof.

##STR00001##

A pharmaceutical composition for treating an influenza virus infectious disease, containing an anti-influenza virus agent as an active ingredient is provided. The anti-influenza virus agent is administered to a patient determined to be positive for the influenza virus infectious disease based on an intraoral image captured using an intraoral imaging apparatus.

A pharmaceutical composition for treating an influenza virus infectious disease, containing an anti-influenza virus agent as an active ingredient is provided. The anti-influenza virus agent is administered to a patient determined to be positive for the influenza virus infectious disease based on an intraoral image captured using an intraoral imaging apparatus.

Provided are certain URAT1 inhibitors, pharmaceutical compositions thereof, and methods of use thereof.

Provided are certain URAT1 inhibitors, pharmaceutical compositions thereof, and methods of use thereof.

Provided are certain URAT1 inhibitors, pharmaceutical compositions thereof, and methods of use thereof.

Provided herein are methods for treating a pulmonary infection in a patient in need thereof, for example, a nontuberculous mycobacterial pulmonary infection for at least one treatment cycle. The method comprises administering to the lungs of the patient a pharmaceutical composition comprising a liposomal complexed aminoglycoside comprising a lipid component comprising electrically neutral lipids and an aminoglycoside. Administration comprises aerosolizing the pharmaceutical composition to provide an aerosolized pharmaceutical composition comprising a mixture of free aminoglycoside and liposomal complexed aminoglycoside, and administering the aerosolized pharmaceutical composition via a nebulizer to the lungs of the patient. The methods provided herein result in a change from baseline on the semi-quantitative scale for mycobacterial culture for a treated patient, and/or NTM culture conversion to negative during or after the administration period.